DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S.
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
J Clin Oncol 2011;
29: 398-405
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.